Univariate Analysis of Demographic Risk Factors for Acute Graft-Versus-Host Disease
| Factor . | No. . | Gr 2-4 GVHD % (SE) . | P . | Gr 3-4 GVHD % (SE) . | P . |
|---|---|---|---|---|---|
| Diagnosis | .21 | .68 | |||
| Leukemia/myelodysplasia | 85 | 27 (5) | 11 (3) | ||
| Hodgkin’s/lymphoma/myeloma | 62 | 33 (6) | 17 (5) | ||
| Solid tumor | 13 | 49 (14) | 16 (10) | ||
| Patient age | .57 | .61 | |||
| 17-32 yrs | 39 | 28 (7) | 10 (5) | ||
| 33-39 yrs | 39 | 23 (7) | 10 (5) | ||
| 40-46 yrs | 43 | 34 (7) | 14 (5) | ||
| 47-61 yrs | 39 | 41 (8) | 20 (7) | ||
| Preparative regimen | .91 | .17 | |||
| Total body irradiation | 33 | 30 (4) | 6 (4) | ||
| No total body irradiation | 127 | 34 (8) | 16 (3) | ||
| GVHD prophylaxis regimen | .03 | .15 | |||
| CSA/methylprednisolone | 50 | 45 (7) | 22 (6) | ||
| FK506/methylprednisolone | 55 | 30 (6) | 13 (5) | ||
| FK506/methotrexate | 55 | 21 (6) | 7 (4) | ||
| Donor sex | .80 | .21 | |||
| Male | 81 | 32 (5) | 10 (3) | ||
| Female | 79 | 30 (5) | 17 (4) | ||
| Female donor—male recipient | .71 | .24 | |||
| Yes | 43 | 28 (7) | 19 (6) | ||
| No | 117 | 32 (4) | 12 (3) | ||
| Parous donor | .61 | .79 | |||
| Yes | 57 | 32 (6) | 13 (5) | ||
| No | 103 | 30 (5) | 14 (3) | ||
| Alloimmunized donor | .51 | .56 | |||
| Yes | 62 | 29 (6) | 12 (4) | ||
| No | 98 | 33 (5) | 15 (4) | ||
| Alloimmunized female donor—male recipient | .57 | .92 | |||
| Yes | 30 | 27 (8) | 10 (5) | ||
| No | 130 | 32 (4) | 14 (3) | ||
| Pair CMV-seronegative | .86 | .70 | |||
| Yes | 19 | 33 (11) | 17 (9) | ||
| No | 141 | 31 (4) | 13 (3) |
| Factor . | No. . | Gr 2-4 GVHD % (SE) . | P . | Gr 3-4 GVHD % (SE) . | P . |
|---|---|---|---|---|---|
| Diagnosis | .21 | .68 | |||
| Leukemia/myelodysplasia | 85 | 27 (5) | 11 (3) | ||
| Hodgkin’s/lymphoma/myeloma | 62 | 33 (6) | 17 (5) | ||
| Solid tumor | 13 | 49 (14) | 16 (10) | ||
| Patient age | .57 | .61 | |||
| 17-32 yrs | 39 | 28 (7) | 10 (5) | ||
| 33-39 yrs | 39 | 23 (7) | 10 (5) | ||
| 40-46 yrs | 43 | 34 (7) | 14 (5) | ||
| 47-61 yrs | 39 | 41 (8) | 20 (7) | ||
| Preparative regimen | .91 | .17 | |||
| Total body irradiation | 33 | 30 (4) | 6 (4) | ||
| No total body irradiation | 127 | 34 (8) | 16 (3) | ||
| GVHD prophylaxis regimen | .03 | .15 | |||
| CSA/methylprednisolone | 50 | 45 (7) | 22 (6) | ||
| FK506/methylprednisolone | 55 | 30 (6) | 13 (5) | ||
| FK506/methotrexate | 55 | 21 (6) | 7 (4) | ||
| Donor sex | .80 | .21 | |||
| Male | 81 | 32 (5) | 10 (3) | ||
| Female | 79 | 30 (5) | 17 (4) | ||
| Female donor—male recipient | .71 | .24 | |||
| Yes | 43 | 28 (7) | 19 (6) | ||
| No | 117 | 32 (4) | 12 (3) | ||
| Parous donor | .61 | .79 | |||
| Yes | 57 | 32 (6) | 13 (5) | ||
| No | 103 | 30 (5) | 14 (3) | ||
| Alloimmunized donor | .51 | .56 | |||
| Yes | 62 | 29 (6) | 12 (4) | ||
| No | 98 | 33 (5) | 15 (4) | ||
| Alloimmunized female donor—male recipient | .57 | .92 | |||
| Yes | 30 | 27 (8) | 10 (5) | ||
| No | 130 | 32 (4) | 14 (3) | ||
| Pair CMV-seronegative | .86 | .70 | |||
| Yes | 19 | 33 (11) | 17 (9) | ||
| No | 141 | 31 (4) | 13 (3) |